A retrospective analysis evaluating the efficacy of ICI monotherapy in patients with advanced HER2-mutant NSCLC showed an ORR of 12% with median PFS and OS of 1.9 and 10.4 months, respectively [21]. Here, ERBB2 is linked to non-small cell lung carcinoma.